Headquarters

5959 Horton St, Floor 7
Emeryville, California 94608

© 2026 Metagenomi

Glenn Pierce, MD, PhD

Dr. Glenn Pierce has more than 35 years of expe­ri­ence in bench-to-bed­side research and devel­op­ment with sev­er­al pub­lic and pri­vate bio­phar­ma­ceu­ti­cal com­pa­nies, includ­ing Bio­gen, Bay­er, Inspi­ra­tion, Avi­gen, Selec­tive Genet­ics, and Amgen. 

Glenn Pierce, MD, PhD 's profile photo

Scientific and Medical Advisor: Physician-researcher, hemophilia patient advocate, Former VP, Medical of World Federation of Hemophilia and Former SVP, Hematology and Gene Therapy, Biogen

At Bio­gen, Dr. Pierce served as Senior Vice Pres­i­dent of hema­tol­ogy, cell and gene ther­a­pies, with over­all R&D respon­si­bil­i­ty for hemo­phil­ia and hemo­glo­binopathies and led the research and clin­i­cal devel­op­ment of the first extend­ed half-life FVIII (Fac­tor VIII) and FIX (Fac­tor IX) Fc fusions. He co-found­ed Ambys Med­i­cines, a cell and gene ther­a­py liv­er regen­er­a­tion start-up, where he served as Chief Med­ical Offi­cer, and most recent­ly served as inter­im Chief Sci­ence Offi­cer of Voy­ager Ther­a­peu­tics, a neu­rode­gen­er­a­tive gene ther­a­py com­pa­ny, where he serves on the Board of Direc­tors. He cur­rent­ly con­sults for a num­ber of next gen­er­a­tion gene ther­a­py com­pa­nies in hemo­phil­ia and oth­er ther­a­peu­tic areas.

Dr. Pierce has served as Vice Pres­i­dent of Med­ical, with the World Fed­er­a­tion of Hemo­phil­ia (WFH). He serves on the U.S. Med­ical and Sci­en­tif­ic Advi­so­ry Coun­cil (MASAC), and pre­vi­ous­ly served on the Board of Direc­tors and as Board Pres­i­dent of the Nation­al Bleed­ing Dis­or­ders Foun­da­tion (NBDF) (pre­vi­ous­ly NHF). 

He was born with severe hemo­phil­ia A and was cured in 2008.

LinkedIn